{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
AC Immune SA Hits New 52-Week High of USD 3.99
AC Immune SA achieved a new 52-week high of USD 3.99 on October 3, 2025, marking a significant milestone for the microcap biotechnology company. Despite this achievement, the company's one-year performance shows a decline, reflecting challenges in its financial metrics and overall market conditions.
AC Immune Forms Golden Cross, Signaling Potential Bullish Breakout Ahead
AC Immune SA has recently experienced a Golden Cross, indicating a potential shift in momentum. The stock rose 3.27% today, outperforming the S&P 500. Despite a challenging year, recent bullish indicators suggest a possible turnaround, prompting increased interest from investors as they monitor future developments.
Is AC Immune SA technically bullish or bearish?
As of June 4, 2025, AC Immune SA shows a mildly bearish trend with mixed signals across time frames, having outperformed the S&P 500 in the short term but significantly underperformed over the past year.
Is AC Immune SA overvalued or undervalued?
As of March 14, 2024, AC Immune SA is considered risky and overvalued due to negative earnings and significant losses, reflected in its financial ratios, and has underperformed the market with a return of -30.58% over the past year.
Is AC Immune SA overvalued or undervalued?
As of March 14, 2024, AC Immune SA is rated risky and overvalued with a negative P/E ratio of -3.48, an EV to EBITDA of -0.93, and a Price to Book Value of 2.00, significantly underperforming peers and the S&P 500.
Is AC Immune SA technically bullish or bearish?
As of June 4, 2025, AC Immune SA's technical trend is mildly bearish, with mixed signals from indicators like MACD, moving averages, and Bollinger Bands suggesting weak bearish sentiment.
Who are in the management team of AC Immune SA?
As of March 2022, the management team of AC Immune SA includes Dr. Douglas Williams (Non-Executive Independent Chairman), Prof. Dr. Andrea Pfeifer (CEO and Co-Founder), Mr. Martin Velasco (Non-Executive Independent Vice Chairman), and several Non-Executive Independent Directors: Dr. Peter Bollmann, Mr. Thomas Graney, and Dr. Werner Lanthaler. This team oversees the company's strategic direction and governance.
What does AC Immune SA do?
AC Immune SA is a Switzerland-based biopharmaceutical company focused on precision medicine for neurodegenerative diseases. As of March 2025, it reported net sales of $1 million and a net loss of $21 million, with a market cap of $201.92 million.
How big is AC Immune SA?
As of Jun 18, AC Immune SA has a market capitalization of 201.92 million and reported net sales of 32.57 million with a net profit of -57.98 million over the latest four quarters. Shareholder's funds are 123.88 million, and total assets amount to 254.80 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
